Swiss GDP Jumps 1.5% in Q2 as Pharma Front-Runs US Tariffs

Switzerland's economy expanded 1.5% quarter-on-quarter in the three months through June, the strongest growth since the third quarter of 2021, as chemical and pharmaceutical companies front-ran US tariffs on drug imports.

"The industrial sector made the largest contribution to growth, which was driven in particular by the chemical and pharmaceutical industry," SECO said in its flash estimate. "That likely comes from the front-running of drug exports to the US, ahead of tariffs of up to 15% on pharmaceuticals that came into effect on July 31," said Ankita Amajuri, Europe economist at Pantheon Macroeconomics.

The reading accelerated sharply from 0.4% growth in the first quarter and 0.2% in the final three months of 2025, according to the State Secretariat for Economic Affairs. Economists surveyed by AWP had forecast growth between 0.2% and 0.4%. SECO attributed roughly two-thirds of the expansion to industry, with the services sector also contributing.

The result gives the Swiss National Bank less reason to respond to growth weakness, with the policy rate at 0%. But the strength may prove temporary — the tariff-driven export surge is a one-off, and the franc's safe-haven appreciation during the Iran war threatens exporter competitiveness.

Tariff Front-Running Distorts the Picture

The US imposed tariffs of up to 15% on pharmaceutical imports effective July 31, prompting Swiss drugmakers to accelerate shipments. The Trump administration separately added new tariffs of up to 12.5% on many Swiss imports in July, replacing the 10% duties in force since February. Swiss GDP last contracted in the third quarter of 2025 as the first round of US tariffs filtered through the economy.

The flash estimate is based partly on estimated inputs and may be revised when full quarterly data are published on September 3. SECO noted a "catch-up effect" following previously weak quarterly figures. The data is adjusted for sporting events, given that Switzerland hosts international organizations including FIFA and the International Olympic Committee.

The concentration of growth in chemicals and pharmaceuticals raises questions about the breadth of the expansion. Manufacturing had already rebounded 1.5% quarter-on-quarter in Q1 after contracting 3.0% in Q4, suggesting the industrial recovery predates the tariff front-running. But the flash estimate provides no detailed sector breakdown beyond SECO's broad assessment, making it difficult to judge how widely the expansion spread.

SNB Holds Steady as Franc Pressures Persist

Switzerland has been less exposed to the global energy shock than other European nations, relying on hydroelectric Alpine dams and a more diverse energy mix. However, the franc's role as a safe haven has meant currency appreciation during the Iran war, undermining exporter competitiveness. The franc has declined against the euro since March, and investors don't expect the SNB to change its policy rate from 0% this year.

Looking ahead, surveys indicate the Swiss economy carried momentum into the third quarter, even if growth will likely soften in the second half of the year, Amajuri said. The closely watched KOF economic barometer climbed above its second-quarter average in July, while purchasing managers' activity eased but remained in growth mode.

The key question for the final release on September 3 will be whether the exceptional industrial contribution was accompanied by broad gains elsewhere or whether Q2 strength was concentrated in a narrow group of export-heavy sectors. If the expansion was indeed narrow, the SNB's easing bias could resurface as tariff effects normalize and the franc's safe-haven premium persists. The IMF projects Swiss GDP growth of 0.8% in 2026 and 1.5% in 2027, with low inflation but trade and energy risks.

This article is for informational purposes only and does not constitute investment advice.